Table 5

Subgroup analyses of complication, treatments and survival outcomes as stratified by years

Total cohort (1995–2014)1995–19992000–20042005–20092010–2014P value
Age (years), median7371.871.87272.80.39
PSA stratification (%)0.25
 0–2060 (8.8)14 (10.9)10 (8.3)14 (8.4)22 (8.1)
 >20–5061 (8.9)20 (15.5)11 (9.2)15 (9.1)15 (5.5)
 >50–10084 (12.3)16 (12.4)11 (9.2)25 (15.2)32 (11.8)
 >100480 (70.2)79 (61.2)88 (73.3)111 (65.3)202 (74.5)
Palliative treatment for urinary obstruction (%)237 (34.6)61 (48.1)55 (45.5)58 (35.2)63 (23.2)<0.01
Skeletal fractures (%)118 (17.2)23 (17.8%)21 (17.5%)32 (19.4%)42 (15.5%)0.30
Hormonal therapy (%)653 (95.3)111 (86.8)111 (92.5)161 (97.6)269 (99.3)<0.01
Types of hormonal therapy (%)<0.01
 Surgical250 (33.8)98 (88.3)64 (57.1)51 (31.7)37 (13.8)
 Medical403 (61.7)13 (11.7)48 (42.9)110 (68.3)232 (86.2)
Time to castrate resistant, months (median)21.423.518.421.619.80.08
Palliative chemotherapy (%)114 (16.6)12 (9.3)16 (13.3)30 (18.2)56 (20.7)0.03
Overall survival, months (median)4541.643.445.347.80.04
  • PSA, prostate specific antigen.